ArticleCombinatorial chemistry & high throughput screening2025
Exploring the Comorbidity Mechanism among Functional Diarrhea, Irritable Bowel Syndrome with Predominant Diarrhea, and Functional Dyspepsia through the Gut-brain Axis and the Pharmacological Mechanisms of Shen-Ling-Bai-Zhu-San Therapy.
Article in Combinatorial chemistry & high throughput screening, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunctional Diarrhea (FDr), Irritable Bowel Syndrome with predominant diarrhea (IBS-D), and Functional Dyspepsia (FD) are common functional gastrointestinal disorders (FGIDs) with significant impacts on quality of life. While the gut-brain axis and key regulators like 5-hydroxytryptamine (5-HT), dopamine (DA), and butyrate are known to play crucial roles in these conditions, the mechanisms underlying their comorbidities remain unclear. Shen-Ling-Bai-Zhu-San (SLBZS), a traditional herbal formula, is effective in treating FGIDs. Still, the specific components and mechanisms mediating its therapeutic effects via the gut-brain axis are not well understood.
methodsThis study identified molecular links among FDr, IBS-D, and FD from the gut-brain axis using integrated biological information. The pharmacological mechanisms of SLBZS were explored through network pharmacology, molecular docking, molecular dynamics simulations, and in vitro bio-layer interferometry (BLI) validation.
resultsA total of 328 common targets were identified among FDr, IBS-D, and FD, with 22 hub genes in the protein-protein interaction (PPI) network associated with 5-HT/DA/butyrate pathways. Virtual screening revealed seven key targets (AKT1, CASP3, VEGFA, INS, CTNNB1, PTGS2, and IL1B) and 14 bioactive components (e.g., diosgenin and luteolin) from SLBZS. Molecular docking indicated strong binding affinities between key components and targets, while molecular dynamics simulations confirmed stable interactions, particularly between PTGS2 and diosgenin/luteolin. BLI experiments further validated the strong binding affinity of PTGS2 for diosgenin.
conclusionThis study elucidates potential targets shared by FDr, IBS-D, and FD through the gut-brain axis, highlighting diosgenin's interaction with PTGS2 as a potential mechanism of SLBZS's therapeutic effects. These findings provide valuable insights into the pharmacological mechanisms of SLBZS in treating FGIDs and suggest new avenues for targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.